Get started
Author

Hugo Gomes da Silva

Institution: Ipsen (France)
OpenAlex ID: A5034150217
Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis
2021 · Prakash Bhuyan, Jennie Medin, et al. · The Lancet · 68
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
2025 · Cynthia Levy, George F. Abouda, et al. · Journal of Hepatology · 32
PDF
The Effect of Raltegravir on the Glucuronidation of Lamotrigine
2009 · Matthijs van Luin, Angela Colbers, et al. · The Journal of Clinical Pharmacology · 30
Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
2021 · Karina Soboleva, Nirmal Kumar Shankar, et al. · The Lancet Global Health · 26
COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron
2023 · Wilhelmine Meeraus, Anke L. Stuurman, et al. · Vaccine · 13
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations
2022 · Michael A Laffan, Sue Rees, et al. · Vaccine · 11
PDF
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
2025 · Cynthia Levy, George Abouda, et al. · Journal of Hepatology · 4
Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic
2023 · Hana Müllerová, Jennie Medin, et al. · BMJ Open · 4
PDF
LBP-027 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis, with limited correlation with pruritus: analyses from the phase III ELATIVE® trial
2025 · David E. Jones, Marco Carbone, et al. · Journal of Hepatology · 3
P30 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis (PBC)
2025 · Jrn M Schattenberg, Pietro Andreone, et al. · Gut · 1
LBP-025 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial
2025 · Mark Swain, Pascale Plas, et al. · Journal of Hepatology · 1
O51 Long-term elafibranor in primary sclerosing cholangitis (PSC): interim safety and efficacy data from the ELMWOOD open-label extension (OLE) trial
2026 · Kuldeep Cheent, Christopher L Bowlus, et al. · Gut
PDF
P56 The efficacy of elafibranor is not affected by body mass index in patients with primary biliary cholangitis (PBC)
2026 · Mohammad Raja, Andreas E Kremer, et al. · Gut
PDF
152 - Elafibranor Improves Fatigue Versus Placebo in Pati@ents With Primary Biliary Cholangitis, With Limited Correlation With Pruritus: Analyses From the Phase Iii Elative® Trial
2026 · Javier Ampuero, David Jones, et al. · Gastroenterología y Hepatología
139 - Treatment With Elafibranor Has No Impact on Bone Health in Patients With Primary Biliary Cholangitis
2026 · Magdalena Salcedo, Jörn M. Schattenberg, et al. · Gastroenterología y Hepatología
P36 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis (PBC) with two years of treatment with elafibranor
2025 · Marlyn J Mayo, Cynthia Levy, et al. · Gut
P26 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE trial
2025 · David E Jones, Marco Carbone, et al. · Gut
P31 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis (PBC): proteomic results from the ELATIVE trial
2025 · Mark Swain, Pascale Plas, et al. · Gut
THU-313 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis
2025 · Jörn M. Schattenberg, Pietro Andreone, et al. · Journal of Hepatology
THU-333 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor
2025 · Marlyn J. Mayo, Cynthia Levy, et al. · Journal of Hepatology
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? – Authors’ reply
2021 · Prakash Bhuyan, Jennie Medin, et al. · The Lancet
PDF
Works count: 21
Citation count: 193
H-index: 6
I10-index: 6
Year
Topic
Type